• Long intracellular half-life (~ 4-6.5 days) of the active antiviral, cidofovirdiphosphate, allows twice-weekly (BIW) dosing • Oral delivery (tablet and pediatric liquid suspension available) • In vitro activity against all 5 families of double-stranded DNA viruses known to cause human disease • No evidence of hematologic or renal toxicity to date: -Unlike Cidofovir, BCV is not a substrate of hOAT 1 (human organic anionic transporter) and thus is not concentrated in renal tubular cells -No drug-related renal dysfunction reported in > 800 subjects Since pediatric patients pose unique toxicity challenges and dsDNA viral infections are common in this age group, we undertook this analysis.
We describe here the results of an analysis of the collective safety experience in pediatric subjects receiving BCV:
• Randomization:
• 1:1 to dosing frequency (QW vs. BIW, unblinded)
• 2:1 to study treatment (BCV vs. placebo, blinded)
• stratified based on absolute lymphocyte count at screening.
Treatment:
• BCV or placebo BIW or QW for at least 6 weeks, up to a maximum of 12 weeks (treatment failures could discontinue blinded treatment and receive up to 12 weeks open-label BCV): • Limited safety data are available
• 110 patients (including 43 children) who provided written consent for data collection
• Treatment:
• Individualized treatment protocols were developed for each subject to allow flexibility in treating subjects with different medical histories and disease states.
• Subjects received treatment for up to 13 weeks; treatment extension beyond 13 weeks required FDA or local regulatory approval.
• Dosing was modified for all ongoing BCV clinical trials in April 2011 to limit treatment to a maximum of 200 mg/week (adults) or 4 mg/kg/week (pediatrics) following treatment-limiting GI events in HCT subjects at a dose of 200 mg BIW in Study CMX001-201. 1 One EIND subject was continuing BCV treatment at time of analysis. 2 One subject in BCV BIW group discontinued at legal guardian's request had an ongoing AE of GI hemorrhage that required study drug discontinuation.
Summary of Demographics
• No deaths were related to study drug • Similar to the adult experience, the most frequently reported AEs were GI disturbances, primarily diarrhea (26%)
• The overall rate of discontinuation due to AEs in pediatric subjects receiving BCV therapy was 11% (16/143)
• Similar to the adult experience, increased serum transaminases (primarily ALT) with no corresponding bilirubin increases were reported in pediatric subjects
• In the placebo-controlled study (CMX001-202), the incidence of ALT/AST elevations in BCV-treated subjects was not higher than placebo recipients, although the sample size was very small
• Following implementation of the SMMP for Study CMX001-202, few subjects were discontinued due to GI events, acute GvHD, or increased serum transaminase concentrations
• As in adult patients, there was no indication of renal or hematologic toxicity in pediatric subjects
